Company: BIAF
Filing Date: 2025-04-15
Form Type: DRS
Source: 0001641172-25-004915
Chunk: 82

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-15
Form: DRS
Chunk 82
---
 value                        
 per share after this offering                                        |     |   |      |     | $ | [  ] |
| Dilution in net tangible book value per share                        
 to new investors in this offering                                    |     |   |      |     | $ | [  ] |

Each $0.10 increase (decrease) in the assumed public offering price of $[___] per share of Common Stock and accompanying April 2025 Warrant would increase (decrease) the as adjusted net tangible book value by $[___] per share of Common Stock and the dilution to new investors by $[___] per share, after deducting the estimated Placement Agent fees and estimated offering expenses payable by us.

We may also increase or decrease the number of shares we are offering. An increase of 100,000 shares in the number of shares of Common Stock offered by us would increase our as adjusted net tangible book value by approximately $[___] million, or approximately $[___] per share of Common Stock, and decrease the dilution per share to investors in this offering by approximately $[___] per share, assuming that the number of shares of Common Stock and accompanying April 2025 Warrants offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated Placement Agent fees and estimated offering expenses payable by us. Similarly, a decrease of 100,000 shares in the number of shares of Common Stock offered by us would decrease our as adjusted net tangible book value by approximately $[___] million, or approximately $[___] per share, and increase the dilution per share to investors in this offering by approximately $[___] per share, assuming the assumed combined offering price of $[ ] per share of Common Stock and accompanying April 2025 Warrant remains the same and after deducting the estimated Placement Agent fees and estimated offering expenses payable by us. The information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering as determined between us and the Placement Agent at pricing.

The information above is based on 15,576,674 shares of Common Stock outstanding as of December 31, 2024, and excludes, as of that date:

| ● | 12,298,124                                                                                
 shares of Common Stock issuable upon the exercise of outstanding warrants with a weighted 
 average exercise price equal to $2.95 per share;                                          |

| ● | 304,125